DK186688D0 - Fremgangsmaade til dyrkning af leukocytter - Google Patents

Fremgangsmaade til dyrkning af leukocytter

Info

Publication number
DK186688D0
DK186688D0 DK186688A DK186688A DK186688D0 DK 186688 D0 DK186688 D0 DK 186688D0 DK 186688 A DK186688 A DK 186688A DK 186688 A DK186688 A DK 186688A DK 186688 D0 DK186688 D0 DK 186688D0
Authority
DK
Denmark
Prior art keywords
leukocytes
cultivating
procedure
cultivating leukocytes
Prior art date
Application number
DK186688A
Other languages
English (en)
Other versions
DK186688A (da
Inventor
Augusto C Ochoa
Barbara J Alter
Paul M Sondel
Fritz H Bach
Original Assignee
Univ Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minnesota filed Critical Univ Minnesota
Publication of DK186688A publication Critical patent/DK186688A/da
Publication of DK186688D0 publication Critical patent/DK186688D0/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2301—Interleukin-1 (IL-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK186688A 1986-08-08 1988-04-06 Fremgangsmaade til dyrkning af leukocytter DK186688D0 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89504286A 1986-08-08 1986-08-08
PCT/US1987/001866 WO1988000970A2 (en) 1986-08-08 1987-08-05 Method of culturing leukocytes

Publications (2)

Publication Number Publication Date
DK186688A DK186688A (da) 1988-04-06
DK186688D0 true DK186688D0 (da) 1988-04-06

Family

ID=25403858

Family Applications (1)

Application Number Title Priority Date Filing Date
DK186688A DK186688D0 (da) 1986-08-08 1988-04-06 Fremgangsmaade til dyrkning af leukocytter

Country Status (6)

Country Link
US (1) US5443983A (da)
AU (1) AU7873187A (da)
DK (1) DK186688D0 (da)
NO (1) NO881491L (da)
WO (1) WO1988000970A2 (da)
ZA (1) ZA875841B (da)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988000970A2 (en) * 1986-08-08 1988-02-11 Regents Of The University Of Minnesota Method of culturing leukocytes
AU2925789A (en) * 1987-12-17 1989-07-19 Browning's Clinical Pathology Services Limited Lymphokine activation of cells for adoptive immunotherapy, e.g. of hiv infection
JP2981486B2 (ja) * 1988-06-14 1999-11-22 メディカル・バイオロジー・インスティチュート 哺乳動物の免疫系研究方法
EP0440742B1 (en) * 1988-10-27 1997-01-15 The Regents Of The University Of Minnesota Liposome immunoadjuvants containing il-2
EP0460101A4 (en) * 1989-02-24 1992-04-15 Immunotherapeutics, Inc. Immobilized cytokines
GR1001034B (el) * 1989-07-21 1993-03-31 Ortho Pharma Corp Μεθοδος διεγερσης του πολλαπλασιασμου λεμφοκυτταρων περιφερειακου αιματος.
US5514392A (en) * 1989-08-30 1996-05-07 Seawell Corporation N.V. Packaging for perishable goods
JP2618497B2 (ja) * 1989-10-03 1997-06-11 鐘淵化学工業株式会社 腫瘍障害細胞誘導剤および腫瘍障害細胞誘導デバイス
EP0578740A4 (en) * 1991-04-05 1995-12-20 Univ Minnesota Method of enhancing the immunotherapeutic activity of immune cells by depletion/positive selection of cell subsets
US5725855A (en) * 1991-04-05 1998-03-10 The United States Of America As Represented By The Department Of Health And Human Services Method of treating tumors with CD8+ -depleted or CD4+ T cell subpopulations
IE922233A1 (en) * 1991-07-10 1993-01-13 Augusto C Ochoa Short-term anti-cd3 stimulation of lymphocytes to increase¹their in vivo activity
JPH07502734A (ja) * 1991-12-31 1995-03-23 ザイモジェネティクス，インコーポレイティド 血液損失を減少する方法および組成物
US5861158A (en) * 1993-11-17 1999-01-19 The United States Of America As Represented By The Deptartment Of Health And Human Services Method and composition for transfer of active tumor-specific immunization from an immunized allogeneic bone marrow donor
US6692964B1 (en) * 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
EP0824594B1 (en) * 1995-05-04 2005-04-06 The United States of America as Representend by The Secretary of the Navy Improved methods for transfecting t cells
US7067318B2 (en) * 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US20020182730A1 (en) * 1995-07-26 2002-12-05 Micheal L. Gruenberg Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
AU727865B2 (en) * 1996-02-21 2001-01-04 Cira Technologies, Inc. Cellular immunotherapy
JP4186013B2 (ja) * 1996-07-15 2008-11-26 暉彬 関根 ウイルス感染症の治療・予防剤、その調製方法
EP1189635A4 (en) * 1999-06-17 2003-04-23 Univ Vermont AUTOLOGOUS ADOPTIVE IMMUNOTHERAPY WITH T-CELLS OR B-CELLS B WHICH HAVE BEEN SENSITIZED TO ANTIGENS-SPECIFIC
US6406699B1 (en) * 1999-10-05 2002-06-18 Gary W. Wood Composition and method of cancer antigen immunotherapy
US20030119185A1 (en) * 2000-02-24 2003-06-26 Xcyte Therapies, Inc. Activation and expansion of cells
US20030235908A1 (en) * 2000-02-24 2003-12-25 Xcyte Therapies, Inc. Activation and expansion of cells
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US6867041B2 (en) * 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) * 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) * 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
WO2001089539A2 (en) * 2000-05-25 2001-11-29 Xcyte Therapies, Inc. Methods for restoring or enhancing t-cell immune surveillance following naturally or artifically induced immunosuppression
FR2821947B1 (fr) * 2001-03-12 2003-05-16 Canon Kk Procede et dispositif de validation de parametres definissant une image
US20030068306A1 (en) * 2001-09-14 2003-04-10 Dilber Mehmet Sirac Medium
US20030134415A1 (en) * 2001-09-19 2003-07-17 Gruenberg Micheal L. Th1 cell adoptive immunotherapy
AU2002341717A1 (en) * 2001-09-17 2003-04-01 Medcell Biologics, Llc. Cell therapy system
US20030134341A1 (en) * 2001-09-19 2003-07-17 Medcell Biologics, Llc. Th1 cell adoptive immunotherapy
US20030165588A1 (en) 2002-03-01 2003-09-04 Unigen Pharmaceuticals, Inc. Identification of free-B-ring flavonoids as potent COX-2 inhibitors
US7108868B2 (en) 2002-03-22 2006-09-19 Unigen Pharmaceuticals, Inc. Isolation of a dual cox-2 and 5-lipoxygenase inhibitor from acacia
US7972632B2 (en) 2003-02-28 2011-07-05 Unigen Pharmaceuticals, Inc. Identification of Free-B-Ring flavonoids as potent COX-2 inhibitors
US20030175272A1 (en) * 2002-03-07 2003-09-18 Medcell Biologics, Inc. Re-activated T-cells for adoptive immunotherapy
US8034387B2 (en) 2002-04-30 2011-10-11 Unigen, Inc. Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments
CA2703698C (en) 2002-04-30 2016-11-22 Unigen Pharmaceuticals, Inc. Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent
WO2004003142A2 (en) * 2002-06-28 2004-01-08 Xcyte Therapies, Inc. Compositions and methods for restoring immune repertoire in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
US20040175373A1 (en) * 2002-06-28 2004-09-09 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
CN1798568B (zh) 2003-04-04 2011-05-11 尤尼根制药公司 用于哺乳动物皮肤护理的双重环氧合酶(cox)以及脂氧合酶(lox)抑制剂的组合物
AU2003300359A1 (en) * 2003-05-08 2004-12-13 Xcyte Therapies, Inc. Generation and isolation of antigen-specific t cells
EP1660109A4 (en) * 2003-09-02 2009-04-08 Unigen Pharmaceuticals Inc FORMULATION OF A MIXTURE OF FREE B-RING FLAVONOIDS AND FLAVANES FOR USE IN THE PREVENTION AND TREATMENT OF COGNITIVE WEAKNESSING AND AGING MEMORY DISORDERS
WO2005030251A1 (en) * 2003-09-22 2005-04-07 Xcyte Therapies, Inc. Compositions and methods to accelerate hematologic recovery
US20060116824A1 (en) * 2004-12-01 2006-06-01 Ishikawa Muriel Y System and method for modulating a humoral immune response
US20060122783A1 (en) * 2004-08-24 2006-06-08 Ishikawa Muriel Y System and method for heightening a humoral immune response
US20060182742A1 (en) * 2004-08-24 2006-08-17 Ishikawa Muriel Y System and method for magnifying a humoral immune response
US20060122784A1 (en) * 2004-12-03 2006-06-08 Ishikawa Muriel Y System and method for augmenting a humoral immune response
US20060047434A1 (en) * 2004-08-24 2006-03-02 Ishikawa Muriel Y System and method related to improving an immune system
US20060047436A1 (en) * 2004-08-25 2006-03-02 Ishikawa Muriel Y System and method for magnifying an immune response
US20060047433A1 (en) * 2004-08-24 2006-03-02 Ishikawa Muriel Y System and method related to enhancing an immune system
US20060047437A1 (en) * 2004-08-25 2006-03-02 Ishikawa Muriel Y System and method for heightening an immune response
US20060095211A1 (en) * 2003-12-05 2006-05-04 Searete Llc, A Limited Liability Corporation Of The State Of Delaware System and method for modulating a cell mediated immune response
US20060047435A1 (en) * 2004-08-24 2006-03-02 Ishikawa Muriel Y System and method related to augmenting an immune system
HUE028467T2 (en) * 2004-02-26 2016-12-28 Immunovative Therapies Ltd A method for producing T-cells for cell therapy
US7592431B2 (en) * 2004-02-26 2009-09-22 Immunovative Therapies, Ltd. Biodegradable T-cell Activation device
EP3202895A1 (en) 2004-03-01 2017-08-09 Immunovative Therapies, Ltd. A composition for use in cell therapy and methods for its preparation
US20060257395A1 (en) * 2005-05-16 2006-11-16 Searete Llc, A Limited Liability Corporation Of The State Of Delaware System and method for magnifying a humoral immune response
US20070207492A1 (en) * 2004-08-24 2007-09-06 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational methods and systems to adjust a humoral immune response
US20070265787A1 (en) * 2004-08-24 2007-11-15 Searete Llc,A Limited Liability Corporation Of The State Of Delaware Computational methods and systems for magnifying cell-mediated immune response
US20070288173A1 (en) * 2004-08-24 2007-12-13 Searete Llc, A Limited Liability Corporation Of The State Of Delware Computational methods and systems to reinforce a humoral immune response
US20070198196A1 (en) * 2004-08-24 2007-08-23 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational systems and methods relating to ameliorating an immune system
US20070265788A1 (en) * 2004-08-24 2007-11-15 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational methods and systems for augmenting cell-mediated immune response
US20070265818A1 (en) * 2004-08-24 2007-11-15 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational methods and systems for heightening cell-mediated immune response
US20070196362A1 (en) * 2004-08-24 2007-08-23 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational methods and systems to bolster an immune response
US20070265817A1 (en) * 2004-08-24 2007-11-15 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational systems and methods relating to fortifying an immune system
US20060047439A1 (en) * 2004-08-24 2006-03-02 Searete Llc, A Limited Liability Corporation Of The State Of Delaware System and method for improving a humoral immune response
US20070265819A1 (en) * 2004-08-24 2007-11-15 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational methods and systems for improving cell-mediated immune response
US7838503B2 (en) * 2005-06-15 2010-11-23 Children's Medical Center Corporation Methods for extending the replicative lifespan of cells
MX2009003764A (es) 2006-10-04 2009-04-22 Janssen Pharmaceutica Nv Preparaciones de celulas presentadoras de antigeno artificiales y su uso en terapias celulares.
US20120052003A9 (en) * 2008-05-16 2012-03-01 Szalay Aladar A Microorganisms for preventing and treating neoplasms accompanying cellular therapy
KR20090127973A (ko) * 2008-06-10 2009-12-15 주식회사 엔케이바이오 자기활성화 림프구 배양 방법
KR20090127974A (ko) * 2008-06-10 2009-12-15 주식회사 엔케이바이오 자기활성화 림프구 배양용 배지 조성물
US8075895B2 (en) 2009-09-22 2011-12-13 Janssen Pharmaceutica N.V. Identification of antigenic peptides from multiple myeloma cells
US10350242B2 (en) 2011-05-03 2019-07-16 Immunovative Therapies Ltd. Methods for handling biological drugs containing living cells
CA2838046C (en) 2011-05-03 2023-03-07 Immunovative Therapies, Ltd. Induction of il-12 using immunotherapy
WO2013177187A2 (en) 2012-05-22 2013-11-28 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
WO2015095744A1 (en) 2013-12-19 2015-06-25 Opexa Therapeutics, Inc. Methods of t cell epitope profiling, making t cell compositions, and treating diseases
US20170044496A1 (en) 2014-04-10 2017-02-16 H. Lee Moffitt Cancer Center And Research Institute, Inc. Enhanced Expansion of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy
US10993997B2 (en) 2014-12-19 2021-05-04 The Broad Institute, Inc. Methods for profiling the t cell repertoire
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
WO2018094167A1 (en) 2016-11-17 2018-05-24 Iovance Biotherapeutics, Inc. Remnant tumor infiltrating lymphocytes and methods of preparing and using the same
WO2018129336A1 (en) 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
HUE065174T2 (hu) 2017-02-12 2024-05-28 Biontech Us Inc HLA-alapú módszerek és készítmények, valamint azok felhasználása
JOP20190224A1 (ar) 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
US11254913B1 (en) 2017-03-29 2022-02-22 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
US20200277573A1 (en) * 2017-11-17 2020-09-03 Iovance Biotherapeutics, Inc. Til expansion from fine needle aspirates and small biopsies
CN111836887A (zh) 2018-01-08 2020-10-27 艾欧凡斯生物治疗公司 产生富含肿瘤抗原特异性t细胞的til产品的方法
SG11202106678PA (en) 2018-12-21 2021-07-29 Biontech Us Inc Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cells
US11246906B2 (en) 2019-06-11 2022-02-15 Alkermes Pharma Ireland Limited Compositions and methods for subcutaneous administration of cancer immunotherapy
US20220364059A1 (en) 2019-07-05 2022-11-17 Case Western Reserve University Priming media and methods for stem cell culture and therapy
US20240150711A1 (en) 2021-03-01 2024-05-09 Dana-Farber Cancer Institute, Inc. Personalized redirection and reprogramming of t cells for precise targeting of tumors
WO2023201369A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0049611B2 (en) * 1980-10-02 1993-12-08 Hooper Trading Co. N.V. A T-cell growth factor, and a process of producing the same
US4464355A (en) * 1981-03-26 1984-08-07 Hooper Trading Co. Serum-free and mitogen-free T-cell growth factor and process for making same
US4683199A (en) * 1983-01-31 1987-07-28 Sloan-Kettering Institute For Cancer Research Interleukin-2 dependent cytotoxic T-cell clones
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
GB8405555D0 (en) * 1984-03-02 1984-04-04 Rees A D M Macrophage activating factors
US4604377A (en) * 1984-03-28 1986-08-05 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2
US4636463A (en) * 1984-04-05 1987-01-13 Scripps Clinic And Research Foundation Antibodies to human interleukin-2 induced by synthetic polypeptides
US4908433A (en) * 1984-04-25 1990-03-13 Sloan-Kettering Institute For Cancer Research Uses of interleukin-2
US4689222A (en) * 1985-01-18 1987-08-25 Mcmichael John Methods and materials for alleviation of pain symptoms of malignant neoplasia
EP0203403B1 (en) * 1985-05-01 1992-10-28 Asahi Kasei Kogyo Kabushiki Kaisha A cloned t cell capable of recognizing tumors and a t cell antigen receptor
US4690915A (en) * 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
WO1988000970A2 (en) * 1986-08-08 1988-02-11 Regents Of The University Of Minnesota Method of culturing leukocytes
US4808151A (en) * 1987-04-27 1989-02-28 E. I. Du Pont De Nemours And Company Simplified method for the preparation of human lymphokine activated killer cells

Also Published As

Publication number Publication date
AU7873187A (en) 1988-02-24
US5443983A (en) 1995-08-22
ZA875841B (en) 1988-04-27
WO1988000970A2 (en) 1988-02-11
NO881491D0 (no) 1988-04-07
NO881491L (no) 1988-04-07
DK186688A (da) 1988-04-06

Similar Documents

Publication Publication Date Title
DK186688A (da) Fremgangsmaade til dyrkning af leukocytter
DK117287D0 (da) Herbicide pyridisulfonamider
DK138287A (da) Fremgangsmaade til fremstilling af ensilage
BG78365A (bg) Инсектицидно средство
DK162806C (da) Fremgangsmaade til bedoevelse af lungeaandende slagtedyr
IT1201113B (it) Composti erbicidi
DK161788A (da) Fremgangsmaade til fremstilling af zidovudin
KR880701527A (ko) 제초제
TR24926A (tr) Diflufenikan kullanan herbisidal usul
ES294250Y (es) Jardinera perfeccionada
DK179188A (da) Fremgangsmaade til dyrkning af mikroorganismer
DK509587A (da) Fremgangsmaade til inhibering af genekspression
DK329787A (da) Fremgangsmaade til fremstilling af mercaptoacylprolinderivater
DK361387D0 (da) Fremgangsmaade til fremstilling af piperidinopyrimidin
DK350288D0 (da) Fremgangsmaade til fremstilling af n-epoxypropyllactamer
DK27988A (da) Fremgangsmaade til fremstilling af substituerede benzaldehyder
DK587287A (da) Fremgangsmaade til fremstilling af 2-guanidinotiazolderivater
DK987D0 (da) Fremgangsmaade til fremstilling af tetrachlorpyri- din
KR880005655U (ko) 양봉용 소초광
DK98287A (da) Fremgangsmaade til fremstilling af imidazolylthiophenaldehyder
DK84585D0 (da) Fremgangsmaade til fremstilling af tensider
ES1000664Y (es) Jardinera perfeccionada
ES292578Y (es) Cierre rapido
RO94640A2 (ro) Procedeu pentru obtinerea azobisciclohexancarbonitrilului
RO94051A2 (ro) Procedeu pentru obtinerea polietilenglicolilor

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment